Trials
8 active
12 in total · 6 in the EU
What this is
- How it works
- An antibody: a lab-made immune protein built to latch onto one target in the body.-mab: monoclonal antibodies WHO name stem
- How it’s given
- “Participants will receive an IV infusion of zolbetuximab once every 2 or 3 weeks.”In the company’s words, NCT07829757 on ClinicalTrials.gov
- Tested for
- Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer (4 trials), Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer (4 trials), Metastatic Gastric Adenocarcinoma or Cancer (4 trials), Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma (4 trials), Metastatic Pancreatic Adenocarcinoma (2 trials), Pancreatic Cancer, Metastatic Pancreatic Cancer, Pharmacokinetics of Zolbetuximab and 4 more
- Main trialPhase 4
- “There is an unmet medical need to treat people with advanced cancer in the stomach and the junction area where the stomach joins the food pipe. These conditions are known as advanced or stomach (gastric) cancer and advanced gastroesophageal junction cancer (GEJ cancer for short). Zolbetuximab is an approved treatment in many countries for people with advanced stomach cancer and advanced GEJ cancer. Some people with these cancers have a protein called Claudin 18.2 on their tumor but they do not have a protein called HER2 (human epidermal growth factor receptor 2) on their surface…”In the company’s words, NCT07829757 on ClinicalTrials.gov
- Other names
- Claudiximab · IMAB362 · Vyloy
Other drugs for Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer
- AvelumabEMD Serono Research & Development Institute, Inc. · Phase 3
- CadonilimabAkeso · Phase 3
- DurvalumabAstraZeneca · Phase 3
- TremelimumabAstraZeneca · Phase 3
- BudigalimabAbbVie · Phase 2/3
- LivmoniplimabAbbVie · Phase 2/3
Coming up4
- 31 DecPhase 1 trial completes · ClinicalTrials.gov
- 30 Jun 2027Phase 2 trial completes · ClinicalTrials.gov
- 30 Sep 2028Phase 3 trial completes · ClinicalTrials.gov
- 31 Jul 2029Phase 4 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials12
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 4Not yet recruiting | 31 Jul 2029 | A Study of Zolbetuximab Given With mFOLFOX6 or CAPOX Chemotherapy in Indian Adults With Gastric Cancer | |
| Phase 3Active, not recruiting | 9 Sep 2022 | A Study to Compare Zolbetuximab (IMAB362) and Chemotherapy With Placebo and Chemotherapy in Adults With Gastric Cancer. | |
| Phase 3Active, not recruiting | 25 Oct 2022 | A Study of Zolbetuximab (IMAB362) Plus CAPOX Compared With Placebo Plus CAPOX as First-line Treatment of Subjects With Claudin (CLDN) 18.2-positive, HER2-negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (GLOW). | |
| Phase 3Recruiting | 30 Sep 2028 | A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer | |
| Phase 2Active, not recruiting | 31 Oct 2026 | A Study of Zolbetuximab (IMAB362) in Adults With Pancreatic Cancer | |
| Phase 2Active, not recruiting | 30 Jun 2027 | A Study of Zolbetuximab (IMAB362) in Adults With Gastric Cancer | |
| Phase 1Active, not recruiting | 31 Dec 2026 | A Study of Zolbetuximab With Chemotherapy in Adults With Pancreatic Cancer | |
| Phase 2Completed | 13 Aug 2015 | Efficacy and Safety Study of Multiple Doses of IMAB362 in Patients With Advanced Gastroesophageal Cancer | |
| Phase 2Completed | 31 Jan 2019 | Efficacy and Safety of IMAB362 in Combination With the EOX Regimen for CLDN18.2-positive Gastric Cancer | |
| Phase 1Completed | 31 May 2010 | Safety and Tolerability Study of Claudiximab in Patients With Advanced Gastroesophageal Cancer | |
| Phase 1Completed | 22 Jan 2021 | A Pharmacokinetic Study of Zolbetuximab (IMAB362) in Chinese Subjects With Locally Advanced Unresectable or Metastatic Gastric or Gastro-esophageal Junction (GEJ) Adenocarcinoma | |
| Phase 2Authorised | not given | Phase II RAINSPOT: a multicentric open label trial of Zolbetuximab-Paclitaxel-Ramucirumab in second line setting for CLDN18.2 positive gastro-esophageal adenocarcinoma |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026